Security
ACIU · AC Immune SA
ACIUNASDAQCommon stockCurrentCIK 1651625Updated Sep 24, 2026
ACIU price & chart
Loading TradingView…
NASDAQ:ACIU on TradingView ↗About the company
AC Immune (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company developing a pipeline of products, including both active immunotherapies and small molecules, targeting key misfolded proteins and pathways for the treatment of multiple neurodegenerative diseases. The company has a growing focus on its wholly owned proprietary clinical-stage programs, including: ACI-7104, an active immunotherapy targeting α-synuclein (α-syn) in Parkinson's disease; and ACI-19764, a small molecule inhibitor of the NLRP3 inflammasome. In addition, an early-stage small molecule development program targeting intracellular a-syn is advancing towards the clinic.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CHFSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCHF | -70,447,000Source | -50,916,000Source | -54,233,000Source | -70,753,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCHF | — | 14,800,000Source | -14,800,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableCHF | -592,000Source | 977,000Source | 770,000Source | -1,073,000Source |
| AdjustmentsForSharebasedPaymentsCHF | 4,396,000Source | 5,470,000Source | 4,365,000Source | 3,330,000Source |
| GeneralAndAdministrativeExpenseCHF | 16,094,000Source | 17,259,000Source | 15,305,000Source | 15,789,000Source |
| InterestPaidClassifiedAsOperatingActivitiesCHF | 174,000Source | 113,000Source | 163,000Source | 470,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesCHF | 1,897,000Source | 1,563,000Source | 595,000Source | 69,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCHF | 1,026,000Source | 683,000Source | 548,000Source | 569,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesCHF | — | — | — | 0Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCHF | 15,000Source | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueCHF | 3,573,000Source | 27,309,000Source | 14,801,000Source | 3,935,000Source |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareCHF/shares | -0.7Source | -0.51Source | -0.64Source | -0.85Source |
| DepreciationRightofuseAssetsCHF | 1,110,000Source | 677,000Source | 543,000Source | 566,000Source |
| DilutedEarningsLossPerShareCHF/shares | -0.7Source | -0.51Source | -0.64Source | -0.85Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCHF | — | 5,500,000Source | 4,400,000Source | 3,300,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedCHF | 690,000Source | 752,000Source | 793,000Source | 750,000Source |
| FinanceCostsCHF | 191,000Source | 133,000Source | 176,000Source | 355,000Source |
| FinanceIncomeCHF | 1,865,000Source | 3,196,000Source | 1,044,000Source | 69,000Source |
| GeneralAndAdministrativeExpenseCHF | 16,094,000Source | 17,259,000Source | 15,305,000Source | 15,789,000Source |
| IncomeTaxExpenseContinuingOperationsCHF | 0Source | 3,000Source | 10,000Source | 13,000Source |
| InterestExpenseOnLeaseLiabilitiesCHF | 174,000Source | 113,000Source | 90,000Source | 68,000Source |
| OtherOperatingIncomeExpenseCHF | 94,000Source | 142,000Source | 1,486,000Source | 1,343,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansCHF | 301,000Source | 1,794,000Source | 2,455,000Source | 1,751,000Source |
| ProfitLossBeforeTaxCHF | -70,447,000Source | -50,913,000Source | -54,223,000Source | -70,740,000Source |
| ProfitLossFromOperatingActivitiesCHF | -69,318,000Source | -52,378,000Source | -53,624,000Source | -70,847,000Source |
| ResearchAndDevelopmentExpenseCHF | 56,436,000Source | 62,570,000Source | 54,606,000Source | 60,336,000Source |
Filing attachments
aciu-20260923xex99d1.htm · 6-K · 2026-09-23
Exhibit 99.1 PRESS RELEASE AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 ●All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated ●Strong immunogenicity demonstrated, with 100% response rate after three immunizations ●Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement ●Discussions with FDA regarding future development path planned for …
Read attachment ↗